» Articles » PMID: 38927095

Advances in Integrated Multi-omics Analysis for Drug-Target Identification

Overview
Journal Biomolecules
Publisher MDPI
Date 2024 Jun 27
PMID 38927095
Authors
Affiliations
Soon will be listed here.
Abstract

As an essential component of modern drug discovery, the role of drug-target identification is growing increasingly prominent. Additionally, single-omics technologies have been widely utilized in the process of discovering drug targets. However, it is difficult for any single-omics level to clearly expound the causal connection between drugs and how they give rise to the emergence of complex phenotypes. With the progress of large-scale sequencing and the development of high-throughput technologies, the tendency in drug-target identification has shifted towards integrated multi-omics techniques, gradually replacing traditional single-omics techniques. Herein, this review centers on the recent advancements in the domain of integrated multi-omics techniques for target identification, highlights the common multi-omics analysis strategies, briefly summarizes the selection of multi-omics analysis tools, and explores the challenges of existing multi-omics analyses, as well as the applications of multi-omics technology in drug-target identification.

Citing Articles

Artificial Intelligence-Driven Computational Approaches in the Development of Anticancer Drugs.

Garg P, Singhal G, Kulkarni P, Horne D, Salgia R, Singhal S Cancers (Basel). 2024; 16(22).

PMID: 39594838 PMC: 11593155. DOI: 10.3390/cancers16223884.


Unravelling the Complexity of HNSCC Using Single-Cell Transcriptomics.

Conde-Lopez C, Marripati D, Elkabets M, Hess J, Kurth I Cancers (Basel). 2024; 16(19).

PMID: 39409886 PMC: 11475296. DOI: 10.3390/cancers16193265.


Integrating text mining with network models for successful target identification: validation in MASH-induced liver fibrosis.

Venhorst J, Hanemaaijer R, Dulos R, Caspers M, Toet K, Attema J Front Pharmacol. 2024; 15:1442752.

PMID: 39399467 PMC: 11466758. DOI: 10.3389/fphar.2024.1442752.


Exploring the design of clinical research studies on the efficacy mechanisms in type 2 diabetes mellitus.

Guan H, Zhao S, Li J, Wang Y, Niu P, Zhang Y Front Endocrinol (Lausanne). 2024; 15:1363877.

PMID: 39371930 PMC: 11449758. DOI: 10.3389/fendo.2024.1363877.

References
1.
Zheng J, Haberland V, Baird D, Walker V, Haycock P, Hurle M . Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020; 52(10):1122-1131. PMC: 7610464. DOI: 10.1038/s41588-020-0682-6. View

2.
Adams R, Steckel M, Nicke B, Pohlenz H . RNAi as a tool for target discovery in early pharmaceutical research. Pharmazie. 2016; 71(1):35-42. View

3.
Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M . KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2015; 44(D1):D457-62. PMC: 4702792. DOI: 10.1093/nar/gkv1070. View

4.
Yamamoto T, Kishton R, Restifo N . Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat Med. 2019; 25(10):1488-1499. DOI: 10.1038/s41591-019-0596-y. View

5.
Lan T, Yuan K, Yan X, Xu L, Liao H, Hao X . LncRNA SNHG10 Facilitates Hepatocarcinogenesis and Metastasis by Modulating Its Homolog SCARNA13 via a Positive Feedback Loop. Cancer Res. 2019; 79(13):3220-3234. DOI: 10.1158/0008-5472.CAN-18-4044. View